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Purpose:  
Cisplatin is commonly used in various chemotherapeutic regimens. However, cisplatin-induced 
nephrotoxicity is a common adverse effect associated with its use. Therefore,  it is crucial to understand 
the nephrotoxic effects of certain cisplatin-based regimens. This study looks at two common cisplatin-
based regimens and compares their extent of nephrotoxicity.  
Methods:  
This study was conducted via systematic review. Various articles were evaluated to determine the effect 
of nephrotoxicity when given cisplatin plus docetaxel or 5-fluorouracil (5-FU). Data was collected based 
on the number of patients experiencing nephrotoxicity with each drug regimen. In particular, we sought 
papers that classified nephrotoxicity based on the grading system set by the World Health Organization 
(WHO). Furthermore, these papers were assessed for quality using CONSORT and Newcastle Ottawa 
grading systems. 
Results:  
When looking at overall nephrotoxicity, those receiving Cisplatin and 5-FU experienced more 
nephrotoxicity. However, we found that Cisplatin in combination with Docetaxel experienced higher WHO 
grade nephrotoxicity than Cisplatin in combination with 5-FU. The Cisplatin and 5-FU treatment regimen 
experienced the most grade 1 nephrotoxicity. The Cisplatin and Docetaxel regimen experienced the most 
grades 2, 3, and 4 nephrotoxicities.  
Conclusion:  
We tested two commonly used cisplatin-based regimens to determine which regimen would produce the 
most nephrotoxicities. By searching various clinical trials and collecting the amount of patients who 
experienced nephrotoxicity, we found that patients treated with Cisplatin and 5-FU experienced slightly 
more nephrotoxicity than those treated with Cisplatin and Docetaxel. This means that patients treated 
with Cisplatin and 5-FU may need closer observation upon administration of this drug regimen to watch 
for any signs or symptoms of nephrotoxicity.  
 
